Research Paper Volume 14, Issue 13 pp 5523—5536

Figure 3. Depletion of ZNF674-AS1 enhanced oxaliplatin resistance of gastric cancer cells. AGS and MKN-45 cells were stably transfected with specific shRNAs against ZNF674-AS1 (sh-ZNF674-AS1-1 and sh-ZNF674-AS1-2) or empty plasmid (shCtrl) (A) Knockdown efficiency of ZNF674-AS1 was validated by qRT-PCR. (B–E) Cell viabilities were examined by CCK-8 assay and the IC₅₀ value to oxaliplatin was calculated. (F) Clone formation of ZNF674-AS1-silenced or negative control AGS and MKN-45 cells, with the treatment of 5μM oxaliplatin. (G) Cell apoptosis was determined by caspase-3 activity assay, with the treatment of 5μM oxaliplatin. (H, I) mRNA levels of MDR1, MRP1 and LRP1 were evaluated by qRT-PCR. Two-way ANOVA for (B, D) Student’s t-test for others.